Thomas K. Equels Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Thomas K. Equels.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Thomas K. Equels. Thomas K. Equels is CEO in AIM ImmunoTech Inc. ($HEB) and CEO & President in AIM ImmunoTech Inc. ($HEB) and CEO / President in HEMISPHERX BIOPHARMA INC ($HEB) and CEO, President in HEMISPHERX BIOPHARMA INC ($HEB) and CEO,Pres,Exec Vice Chairman in HEMISPHERX BIOPHARMA INC ($HEB) and CEO,President in HEMISPHERX BIOPHARMA INC ($HEB) and CFO, Pres.,Sec., Vice Chairman in HEMISPHERX BIOPHARMA INC ($HEB) and CFO, Vice Chairman, Secretary in HEMISPHERX BIOPHARMA INC ($HEB) and CFO,Vice Chairman,Secretary in HEMISPHERX BIOPHARMA INC ($HEB) and Director in HEMISPHERX BIOPHARMA INC ($HEB) and Exec Vice Chairman of Board in HEMISPHERX BIOPHARMA INC ($HEB) and Exec Vice Chairman, Secretary in HEMISPHERX BIOPHARMA INC ($HEB) and Exec Vice Chairman,Secretary in HEMISPHERX BIOPHARMA INC ($HEB) and Exec. Vice Chairman/CEO/Pres. in HEMISPHERX BIOPHARMA INC ($HEB) and Exec.Vice Chairman/CEO/Pres. in AIM ImmunoTech Inc. ($HEB) and General Counsel in HEMISPHERX BIOPHARMA INC ($HEB) and Vice Chairman of Board in HEMISPHERX BIOPHARMA INC ($HEB).
Latest Insider Trading Transactions of Thomas K. Equels
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24 2021 | HEB | AIM ImmunoTech Inc ... | EQUELS THOMAS K. | CEO & President | Buy | P | 2.26 | 11,062 | 25,000 | 209,630 | 198.6 K to 209.6 K (+5.57 %) |
| Dec 17 2020 | HEB | AIM ImmunoTech Inc ... | EQUELS THOMAS K. | CEO | Buy | P | 1.72 | 14,535 | 25,000 | 198,568 | 184 K to 198.6 K (+7.90 %) |
| Nov 13 2020 | HEB | AIM ImmunoTech Inc ... | EQUELS THOMAS K. | CEO | Option Exercise | A | 1.96 | 300,000 | 588,000 | 300,000 | |
| Sep 03 2020 | HEB | AIM ImmunoTech Inc ... | EQUELS THOMAS K. | CEO & President | Buy | P | 2.03 | 12,316 | 25,001 | 184,033 | 171.7 K to 184 K (+7.17 %) |
| Aug 21 2020 | HEB | AIM ImmunoTech Inc ... | EQUELS THOMAS K. | CEO | Buy | P | 2.33 | 10,730 | 25,001 | 171,717 | 161 K to 171.7 K (+6.67 %) |
| Aug 14 2020 | HEB | AIM ImmunoTech Inc ... | EQUELS THOMAS K. | CEO | Option Exercise | A | 3.05 | 300,000 | 915,000 | 300,000 | |
| Jan 02 2020 | HEB | AIM ImmunoTech Inc ... | EQUELS THOMAS K. | Exec.Vice Chairman/ ... | Grant | A | 0.53 | 14,741 | 7,813 | 160,990 | 146.2 K to 161 K (+10.08 %) |
| Dec 16 2019 | HEB | AIM ImmunoTech Inc ... | EQUELS THOMAS K. | Exec.Vice Chairman/ ... | Grant | A | 0.44 | 17,960 | 7,813 | 146,249 | 128.3 K to 146.2 K (+14.00 %) |
| Dec 02 2019 | HEB | AIM ImmunoTech Inc ... | EQUELS THOMAS K. | Exec.Vice Chairman/ ... | Grant | A | 0.40 | 19,531 | 7,812 | 128,289 | 108.8 K to 128.3 K (+17.96 %) |
| Nov 18 2019 | HEB | AIM ImmunoTech Inc ... | EQUELS THOMAS K. | Exec.Vice Chairman/ ... | Grant | A | 0.47 | 16,622 | 7,812 | 108,758 | 92.1 K to 108.8 K (+18.04 %) |
| Oct 31 2019 | HEB | AIM ImmunoTech Inc ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Grant | A | 0.50 | 15,625 | 7,813 | 92,136 | 76.5 K to 92.1 K (+20.42 %) |
| Oct 17 2019 | HEB | AIM ImmunoTech Inc ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Grant | A | 0.58 | 13,470 | 7,813 | 76,511 | 63 K to 76.5 K (+21.37 %) |
| Jun 27 2019 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 4.37 | 2,632 | 11,502 | 63,041 | 60.4 K to 63 K (+4.36 %) |
| Jun 21 2019 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 4.03 | 29,404 | 118,498 | 1,393,611 | 1.4 M to 1.4 M (+2.16 %) |
| Jun 17 2019 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | C | 0.00 | 227,500 | 0 | 1,364,207 | 1.1 M to 1.4 M (+20.01 %) |
| Jun 17 2019 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | C | 0.00 | 325,000 | 0 | 1,136,707 | 811.7 K to 1.1 M (+40.04 %) |
| Mar 19 2019 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.18 | 13,400 | 2,352 | 811,707 | 798.3 K to 811.7 K (+1.68 %) |
| Mar 12 2019 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Option Exercise | X | 1,000.00 | 65 | 65,000 | 0 | |
| Mar 12 2019 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | X | 0.00 | 325,000 | 0 | 325,000 | 0 to 325 K |
| Mar 12 2019 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | X | 0.00 | 65 | 0 | 65 | 0 to 65 |
| Jan 30 2019 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Option Exercise | A | 0.22 | 426,136 | 93,750 | 426,136 | |
| Dec 03 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.20 | 6,000 | 1,176 | 798,307 | 792.3 K to 798.3 K (+0.76 %) |
| Dec 03 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.19 | 334 | 65 | 792,307 | 792 K to 792.3 K (+0.04 %) |
| Dec 03 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.19 | 300 | 58 | 791,973 | 791.7 K to 792 K (+0.04 %) |
| Dec 03 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.19 | 50 | 10 | 791,673 | 791.6 K to 791.7 K (+0.01 %) |
| Dec 03 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.19 | 2,400 | 463 | 791,623 | 789.2 K to 791.6 K (+0.30 %) |
| Dec 03 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.19 | 9,557 | 1,816 | 789,223 | 779.7 K to 789.2 K (+1.23 %) |
| Dec 03 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.19 | 5 | 1 | 779,666 | 779.7 K to 779.7 K (0.00 %) |
| Dec 03 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.19 | 1,354 | 256 | 779,661 | 778.3 K to 779.7 K (+0.17 %) |
| Nov 29 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Grant | A | 0.00 | 2,500 | 0 | 778,307 | 775.8 K to 778.3 K (+0.32 %) |
| Nov 16 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Option Exercise | A | 0.22 | 1,000 | 220 | 1,000 | |
| Oct 29 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.20 | 3,500 | 711 | 775,807 | 772.3 K to 775.8 K (+0.45 %) |
| Oct 25 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.20 | 100,000 | 20,000 | 772,307 | 672.3 K to 772.3 K (+14.87 %) |
| Oct 19 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Option Exercise | A | 0.22 | 284,091 | 62,500 | 284,091 | |
| Jul 27 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.29 | 34,483 | 10,000 | 672,306 | 637.8 K to 672.3 K (+5.41 %) |
| Jul 23 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Buy | P | 0.31 | 112,904 | 35,000 | 637,823 | 524.9 K to 637.8 K (+21.51 %) |
| Jul 19 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Option Exercise | A | 0.31 | 161,290 | 50,000 | 161,290 | |
| May 18 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Option Exercise | J | 0.30 | 300,000 | 90,000 | 795,833 | |
| May 18 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Option Exercise | A | 0.30 | 250,000 | 75,000 | 250,000 | |
| Apr 30 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | CEO, President | Buy | P | 0.32 | 32,000 | 10,240 | 524,919 | 492.9 K to 524.9 K (+6.49 %) |
| Apr 19 2018 | HEB | HEMISPHERX BIOPHAR ... | EQUELS THOMAS K. | Exec. Vice Chairman ... | Option Exercise | A | 0.38 | 125,000 | 47,500 | 125,000 | |
| Mar 01 2018 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Exec. Vice Chairman ... | Option Exercise | A | 0.37 | 371,622 | 137,500 | 371,622 | |
| Sep 01 2017 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO / President | Option Exercise | A | 0.36 | 24,463 | 8,807 | 24,463 | |
| Aug 16 2017 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO / President | Option Exercise | A | 0.41 | 21,336 | 8,748 | 21,336 | |
| Aug 01 2017 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO / President | Option Exercise | A | 0.42 | 20,786 | 8,730 | 20,786 | |
| Jul 17 2017 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO / President | Option Exercise | A | 0.48 | 18,124 | 8,700 | 18,124 | |
| Jul 05 2017 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO / President | Option Exercise | A | 0.49 | 14,214 | 6,965 | 14,214 | |
| Jun 19 2017 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO / President | Option Exercise | A | 0.54 | 14,293 | 7,718 | 14,293 | |
| Jun 09 2017 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO / President | Option Exercise | J | 0.56 | 300,000 | 168,000 | 495,833 | |
| Apr 27 2017 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO, President | Buy | P | 0.69 | 72,464 | 50,000 | 492,919 | 420.5 K to 492.9 K (+17.23 %) |
| Apr 11 2017 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO, President | Buy | P | 0.50 | 200,000 | 100,000 | 420,455 | 220.5 K to 420.5 K (+90.72 %) |
| Dec 23 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO, President | Buy | P | 0.73 | 68,493 | 50,000 | 220,455 | 152 K to 220.5 K (+45.07 %) |
| Nov 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 1.00 | 10,000 | 10,000 | 151,962 | 142 K to 152 K (+7.04 %) |
| Jul 08 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO, President | Buy | P | 0.12 | 48,000 | 5,683 | 1,703,548 | 1.7 M to 1.7 M (+2.90 %) |
| Jul 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 0.12 | 28,000 | 3,321 | 1,655,548 | 1.6 M to 1.7 M (+1.72 %) |
| Jul 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 0.12 | 28,000 | 3,343 | 1,627,548 | 1.6 M to 1.6 M (+1.75 %) |
| Jul 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 0.12 | 28,000 | 3,332 | 1,599,548 | 1.6 M to 1.6 M (+1.78 %) |
| Jul 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 0.12 | 28,000 | 3,360 | 1,571,548 | 1.5 M to 1.6 M (+1.81 %) |
| Jul 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 0.12 | 28,000 | 3,321 | 1,655,548 | 1.6 M to 1.7 M (+1.72 %) |
| Jul 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 0.12 | 29,000 | 3,471 | 1,543,548 | 1.5 M to 1.5 M (+1.91 %) |
| Jul 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 0.12 | 28,000 | 3,343 | 1,627,548 | 1.6 M to 1.6 M (+1.75 %) |
| Jul 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 0.12 | 30,000 | 3,597 | 1,514,548 | 1.5 M to 1.5 M (+2.02 %) |
| Jul 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 0.12 | 28,000 | 3,332 | 1,599,548 | 1.6 M to 1.6 M (+1.78 %) |
| Jul 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 0.12 | 28,000 | 3,360 | 1,571,548 | 1.5 M to 1.6 M (+1.81 %) |
| Jul 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 0.12 | 29,000 | 3,471 | 1,543,548 | 1.5 M to 1.5 M (+1.91 %) |
| Jul 01 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,President | Buy | P | 0.12 | 30,000 | 3,597 | 1,514,548 | 1.5 M to 1.5 M (+2.02 %) |
| Jun 10 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO / President | Option Exercise | J | 0.14 | 300,000 | 42,000 | 2,350,000 | |
| Mar 21 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,Pres,Exec Vice ... | Buy | P | 0.13 | 30,000 | 3,966 | 1,484,548 | 1.5 M to 1.5 M (+2.06 %) |
| Mar 14 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,Pres,Exec Vice ... | Buy | P | 0.16 | 10,000 | 1,618 | 10,000 | 0 to 10 K |
| Mar 14 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,Pres,Exec Vice ... | Buy | P | 0.16 | 30,000 | 4,692 | 30,000 | 0 to 30 K |
| Mar 10 2016 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CEO,Pres,Exec Vice ... | Buy | P | 0.16 | 30,000 | 4,890 | 30,000 | 0 to 30 K |
| Aug 14 2015 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CFO, Pres.,Sec., Vi ... | Buy | P | 0.18 | 50,000 | 9,005 | 1,384,548 | 1.3 M to 1.4 M (+3.75 %) |
| Aug 14 2015 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CFO, Pres.,Sec., Vi ... | Buy | P | 0.18 | 12,600 | 2,268 | 1,334,548 | 1.3 M to 1.3 M (+0.95 %) |
| Aug 14 2015 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CFO, Pres.,Sec., Vi ... | Buy | P | 0.18 | 16,504 | 2,967 | 1,321,948 | 1.3 M to 1.3 M (+1.26 %) |
| Jun 10 2015 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CFO,Vice Chairman,S ... | Option Exercise | J | 0.25 | 300,000 | 75,000 | 2,050,000 | |
| Apr 28 2015 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CFO, Vice Chairman, ... | Buy | P | 0.24 | 100,000 | 24,430 | 1,305,444 | 1.2 M to 1.3 M (+8.30 %) |
| Apr 21 2015 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CFO, Vice Chairman, ... | Buy | P | 0.24 | 100,000 | 23,910 | 1,205,444 | 1.1 M to 1.2 M (+9.05 %) |
| Apr 15 2015 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | CFO, Vice Chairman, ... | Buy | P | 0.23 | 100,000 | 22,540 | 1,105,444 | 1 M to 1.1 M (+9.95 %) |
| Aug 02 2013 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Exec Vice Chairman, ... | Option Exercise | J | 0.25 | 150,000 | 37,500 | 1,450,000 | |
| Jun 06 2013 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Exec Vice Chairman, ... | Option Exercise | J | 0.31 | 300,000 | 93,000 | 1,300,000 | |
| Jun 11 2012 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Vice Chairman of Bo ... | Option Exercise | J | 0.31 | 300,000 | 93,000 | 1,000,000 | |
| Jun 07 2012 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Exec Vice Chairman ... | Option Exercise | J | 0.29 | 100,000 | 29,000 | 700,000 | |
| Jun 27 2011 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | General Counsel | Option Exercise | J | 0.41 | 300,000 | 123,000 | 1,091,196 | |
| Jul 01 2010 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Director | Option Exercise | P | 0.66 | 300,000 | 198,000 | 791,196 | |
| Sep 30 2009 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Director | Grant | A | 2.10 | 7,714 | 16,199 | 7,714 | 0 to 7.7 K |
| Sep 30 2009 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Director | Grant | A | 2.12 | 11,741 | 24,891 | 11,741 | 0 to 11.7 K |
| Jun 12 2009 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Director | Grant | A | 0.55 | 68,182 | 37,500 | 68,182 | 0 to 68.2 K |
| Jun 26 2009 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Director | Grant | A | 0.50 | 99,483 | 49,742 | 99,483 | 0 to 99.5 K |
| Mar 18 2009 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Director | Option Exercise | A | 0.51 | 491,196 | 250,510 | 491,196 | |
| Mar 18 2009 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Director | Grant | A | 0.40 | 93,750 | 37,500 | 93,750 | 0 to 93.8 K |
| Mar 18 2009 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Director | Grant | A | 0.40 | 375,000 | 150,000 | 375,000 | 0 to 375 K |
| Mar 18 2009 | HEB | HEMISPHERX BIOPHAR ... | Equels Thomas K. | Director | Grant | A | 0.36 | 39,778 | 14,320 | 39,778 | 0 to 39.8 K |
Page: 1